COMPANY

Dauntless Biotherapeutics, Inc.

dauntlessbiotherapeutics.com · 2 sources

“We are developing an Antibody Drug Conjugate (ADC), to an undisclosed Tumor Associated Antigen (TAA), to treat cancers of unmet need.” Source · checked Oct 13, 2026

Keywords: oncology Antibody Drug Conjugate Tumor Associated Antigen antibody antibody-drug conjugate ADC

Location: Carlsbad, CA · source · Oct 13, 2026

Profile checked Oct 13, 2026

Sourced facts

Each item links to its source and was checked by an independent review on Oct 13, 2026 (San Diego batch).

Therapeutic areas or services

We are developing an Antibody Drug Conjugate (ADC), to an undisclosed Tumor Associated Antigen (TAA), to treat cancers of unmet need. · dauntlessbiotherapeutics.com · checked Oct 13, 2026

Headquarters address

Carlsbad, CA · dauntlessbiotherapeutics.com · checked Oct 13, 2026

Funding and NIH signals

NIH award NIH awarded $400K (SBIR Phase I 1R43CA306683-01A1, new, notice Aug 11, 2026). NIH RePORTER 1R43CA306683-01A1 (Aug 11, 2026)
Evidence (1 event)
- Aug 11, 2026 · NIH RePORTER 1R43CA306683-01A1
  Organization: DAUNTLESS BIOTHERAPEUTICS, INC.; City/State: San Diego, CA; Project number: 1R43CA306683-01A1; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-11; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Overcoming Breast Cancer Resistance with a Dual-Function Antibody Therapeutic; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals